AtriCure (ATRC) vs OraSure Technologies (OSUR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
AtriCure (ATRC) has outperformed OraSure Technologies (OSUR) over the past year, gaining 56.2% versus a gain of 18.0%. Over five years, ATRC leads with a -25.3% price change compared with -64.5% for OSUR. AtriCure is the larger company by market cap ($2.69 billion vs $261.7 million), about 10.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATRC | OSUR |
|---|---|---|
| Share price | $52.84 | $3.80 |
| Market cap | $2.69B | $261.74M |
| 1-day change | -0.88% | +1.74% |
| YTD return | +34.76% | +54.13% |
| 1-year return | +56.24% | +18.04% |
| 5-year return | -25.30% | -64.51% |
| P/E ratio (TTM) | 251.62 | — |
| Forward P/E | 121.76 | — |
| EPS (TTM) | $0.21 | $-0.69 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $534.53M | — |
| Revenue growth (YoY) | +14.88% | — |
| Net income (latest FY) | $-11.45M | — |
| Gross margin | 74.98% | — |
| Operating margin | -1.77% | — |
| Net margin | -2.14% | — |
| 52-week high | $61.70 | $4.58 |
| 52-week low | $25.36 | $2.08 |
| Distance from 52-week high | -14.36% | -17.14% |
| Analyst consensus | buy | none |
| Avg. price target upside | +3.88% | +5.40% |
| Average volume | 1.09M | 480.26K |
| Shares outstanding | 50.87M | 68.97M |
| Employees | 1,350 | 500 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AtriCure is about 10.3 times larger than OraSure Technologies by market value ($2.69B vs $261.74M).
- ATRC has outperformed OSUR by 38.2 percentage points over the past year.
About AtriCure
ATRC stock →AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally.
Health Care · Medical/Dental Instruments · 1,350 employees
About OraSure Technologies
OSUR stock →OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally. It offers OraQuick Rapid HIV test, OraQuick HIV self-test, OraQuick HIV self-test(international), OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, SickleSCAN test, and OraSure oral fluid collection device for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.
Health Care · Medical/Dental Instruments · 500 employees
ATRC vs OSUR FAQ
Which is bigger, AtriCure or OraSure Technologies?
AtriCure (ATRC) is larger, with a market capitalization of $2.69B compared with $261.74M for OraSure Technologies (OSUR).
Which stock has performed better over the past year, ATRC or OSUR?
ATRC returned +56.24% over the past 12 months, compared with +18.04% for OSUR (price return, excluding dividends). Past performance does not predict future results.
Are AtriCure and OraSure Technologies in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.